| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1374341 | Bioorganic & Medicinal Chemistry Letters | 2011 | 4 Pages |
Abstract
In our ongoing efforts to develop CGRP receptor antagonists for the treatment of migraine, we aimed to improve upon telecagepant by targeting a compound with a lower projected clinical dose. Imidazoazepanes were identified as potent caprolactam replacements and SAR of the imidazole yielded the tertiary methyl ether as an optimal substituent for potency and hERG selectivity. Combination with the azabenzoxazinone spiropiperidine ultimately led to preclinical candidate 30 (MK-2918).
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Daniel V. Paone, Diem N. Nguyen, Anthony W. Shaw, Christopher S. Burgey, Craig M. Potteiger, James Z. Deng, Scott D. Mosser, Christopher A. Salvatore, Sean Yu, Shane Roller, Stefanie A. Kane, Harold G. Selnick, Joseph P. Vacca, Theresa M. Williams,